Integra Lifesciences Holdings Corp (NASDAQ:IART) saw a significant decline in short interest in August. As of August 31st, there was short interest totalling 943,000 shares, a decline of 18.9% from the July 31st total of 1,163,200 shares. Based on an average daily volume of 433,200 shares, the short-interest ratio is presently 2.2 days. Currently, 1.3% of the company’s stock are short sold.
NASDAQ IART traded down $0.47 during trading on Friday, reaching $61.40. 367,778 shares of the company’s stock were exchanged, compared to its average volume of 502,058. The business has a 50 day moving average price of $61.45 and a 200-day moving average price of $55.12. The stock has a market capitalization of $5.37 billion, a P/E ratio of 25.37, a PEG ratio of 1.97 and a beta of 1.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.76 and a quick ratio of 1.82. Integra Lifesciences has a fifty-two week low of $42.14 and a fifty-two week high of $66.41.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. The firm had revenue of $383.60 million for the quarter, compared to the consensus estimate of $373.29 million. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 earnings per share. On average, analysts forecast that Integra Lifesciences will post 2.73 earnings per share for the current year.
A number of analysts recently issued reports on IART shares. ValuEngine downgraded Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. JMP Securities lifted their target price on Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. Zacks Investment Research raised Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a research report on Monday, September 2nd. BidaskClub downgraded Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 28th. Finally, Wells Fargo & Co lifted their target price on Integra Lifesciences from $55.00 to $68.00 and gave the company a “market perform” rating in a research report on Thursday, July 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $62.67.
In other news, VP John Mooradian sold 9,249 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $62.53, for a total value of $578,339.97. Following the sale, the vice president now directly owns 18,706 shares in the company, valued at $1,169,686.18. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel L. Reuvers sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the sale, the vice president now owns 35,392 shares in the company, valued at $2,123,520. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 371,571 shares of company stock worth $22,617,425. Corporate insiders own 4.50% of the company’s stock.
Several hedge funds have recently modified their holdings of the stock. Boston Partners boosted its stake in shares of Integra Lifesciences by 1.3% in the second quarter. Boston Partners now owns 13,119 shares of the life sciences company’s stock valued at $733,000 after buying an additional 171 shares during the period. Municipal Employees Retirement System of Michigan lifted its stake in Integra Lifesciences by 1.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 13,080 shares of the life sciences company’s stock worth $731,000 after purchasing an additional 190 shares during the last quarter. Zions Bancorporation N.A. lifted its stake in Integra Lifesciences by 5.9% during the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock worth $243,000 after purchasing an additional 242 shares during the last quarter. LPL Financial LLC lifted its stake in Integra Lifesciences by 4.4% during the second quarter. LPL Financial LLC now owns 5,754 shares of the life sciences company’s stock worth $319,000 after purchasing an additional 242 shares during the last quarter. Finally, Advisor Group Inc. lifted its stake in Integra Lifesciences by 0.9% during the first quarter. Advisor Group Inc. now owns 30,842 shares of the life sciences company’s stock worth $1,719,000 after purchasing an additional 282 shares during the last quarter. Institutional investors and hedge funds own 81.91% of the company’s stock.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Recommended Story: What is Green Investing?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.